Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineAdjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

In this trial, disease-free survival was longer with adjuvant nivolumab than with placebo in the intention-to-treat population and among patients with a PD-L1 expression level of 1% or more in patients with high-risk muscle-invasive urothelial carcinoma who had had radical surgery.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form